Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 70

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 70
---
ger, the combined company is expected to retain four of the current directors of MIRA as were in office prior to the Merger, comprised of Matthew Pratt Whalen, CPA; Erez Aminov; Edward MacPherson and Dr. Matthew Paul Del Giudice, and for the fifth director, Dr. Denil Nanji Shekhat, will be replaced by Kelly Stackpole, the current CEO of SKNY, with each until their respective successors are duly elected or appointed and qualified or their earlier death, resignation or removal

Regulatory Approvals

We are not aware of any federal, state, local or foreign regulatory requirements that must be complied with or approvals that must be obtained prior to completion of the merger pursuant to the merger agreement, other than compliance with applicable federal and state securities laws, the filing of articles of merger as required under the Florida Business Corporation Act and various state governmental authorizations.

Appraisal Rights and Dissenters’ Rights

Pursuant to Section 607.1302 of the Florida Business Corporation Act, the shareholders of MIRA will not be entitled to appraisal rights or dissenters rights as a result of the merger.

Additional Information

For a detailed description of the Merger Agreement, including representations, warranties, covenants, and other terms, please refer to the full text of the Merger Agreement filed as Annex A to this Proxy Statement.

| 35 |

<div align='center'>DESCRIPTION OF SKNY’S BUSINESS</div>

Overview

SKNY Pharmaceuticals, Inc. (“SKNY”) is a preclinical-stage company developing SKNY-1, a novel oral therapeutic designed to modulate cannabinoid receptors CB1 and CB2, as well as selectively inhibit monoamine oxidase B (MAO-B), an enzyme involved in dopamine metabolism and addiction regulation. SKNY-1 is being developed for two lead indications: weight loss and nicotine dependence. SKNY holds exclusive rights to SKNY-1 in the United States, Canada, and Mexico. Despite existing treatments in both therapeutic areas, SKNY-1 is believed to offer the potential for improved efficacy with a favorable safety profile, making it a promising candidate for both the weight loss and nicotine dependence markets.

Obesity and smoking share pharmacological and physiological connections that intertwine through neurotransmitter systems, metabolic pathways, and behavioral mechanisms. These links influence how each condition affects the other, smoking can suppress weight gain, while quitting often swaps nicotine craving for food craving, as both hit dopamine pathways. (Source: Cell Press, Neuron Review)

SK